Skip to main content

Scripps Institute Joins GeneGo's Cardiac Pathways Group

NEW YORK (GenomeWeb News) – GeneGo said today that the Scripps Translational Science Institute has become the first member of a consortium that the company is building to develop a systems biology software and database platform for cardiovascular diseases. 
 
The company plans to add other members from the pharmaceutical and academic communities to the MetaMiner Cardiac Consortium. The members of the consortium will have a say in what cardiac-specific ontologies and pathway maps the company will incorporate into the MetaMiner product.
 
Scripps and any future consortium members, in return, will have free access to the product GeneGo develops. The company plans to put the product on the market six to 12 months after the consortium members have access to it, Julie Bryant, GeneGo’s VP of business development and marketing, told GenomeWeb Daily News today.
 
The company recently released a similar MetaMiner software and database platform for cystic fibrosis.
 
Cardiac Consortium memberships last for three years, and the company should be ready to release a MetaMiner Cardiac product within one to two years, Bryant said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.